PMA device
Gem 21S (Growth Enhanced Matrix)
Lynch Biologics, LLC · Bone Grafting Material, Dental, With Biologic Component (NPZ, Class III) · First FDA decision Sep 22, 2006, newest Sep 3, 2008Gum diseaseTooth loss and dental implants
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
PMA pathway
Device trials
0
Naming "Gem 21S"
MAUDE reports
0
Brand "Gem 21S", since 2015
PubMed studies
6
Mentioning "Gem 21S"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Gem 21S (Growth Enhanced Matrix)
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
- GEM 21S (GROWTH ENHANCED MATRIX)PMA supplement
P040013-S012 · Decided Sep 3, 2008 · 285 days after receipt · Normal 180 Day Track No User Fee
Device type: Bone grafting material, dental, with biologic component (NPZ) · Dentistry & Oral Surgery
1 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Gem 21S", any status and sponsor, newest update first.
No registered device study names "Gem 21S".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Gem 21S", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code NPZ
34 reports: 0 malfunction, 33 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Gem 21S"[tiab]. The summary above synthesizes these.
- Clinical evaluation of GEM 21S(®) and a collagen membrane with a coronally advanced flap as a root coverage procedure in the treatment of gingival recession defects: A comparative study.
Singh P, Suresh DK · J Indian Soc Periodontol · 2012
- Pre-clinical models for oral and periodontal reconstructive therapies.
Pellegrini G, Seol YJ, Gruber R, et al. · J Dent Res · 2009Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- The Role of Biologically Active Materials in Peri-Implant Diseases.
Mercado F, Loch C · J Clin Med · 2026Review
- Multiple Gingival Recession Defects Treated with Coronally Advanced Flap and Either the VISTA Technique Enhanced with GEM 21S or Periosteal Pedicle Graft: A 9-Month Clinical Study.
Dandu SR, Murthy KR · Int J Periodontics Restorative Dent · 2016Randomized Controlled Trial
- Regenerative Endodontic Treatment of an Immature Necrotic Molar with Arrested Root Development by Using Recombinant Human Platelet-derived Growth Factor: A Case Report.
Zhujiang A, Kim SG · J Endod · 2016Case Reports
- Release, biological potency, and biochemical integrity of recombinant human platelet-derived growth factor-BB (rhPDGF-BB) combined with Augment(TM) Bone Graft or GEM 21S beta-tricalcium phosphate (beta-TCP).
Young CS, Ladd PA, Browning CF, et al. · J Control Release · 2009Research Support, Non-U.S. Gov't
Other devices of this type
Also filed under product code NPZ.
- Infuse Bone GraftMedtronic, Inc. · PMA 2026
- Gem 21S Growth Factor Enhanced MatrixLynch Biologics, LLC · PMA 2011
- GEM21S Growth Factor Enhanced MatrixLynch Biologics, LLC · PMA 2020
- Pepgen P-15, Pepgen P-15 Flow & Pepgen P-15 PuttyCeramed Corp. · PMA 2007
- Pepgen P-15 Dental Bone Grafting Material with Biologic ComponentCeramed Corp. · PMA 2006
- GEM215 Growth Factor Enhanced MatrixLynch Biologics, LLC · PMA 2020
- Gem 21SGROWTH Factor Enhanced MatrixLynch Biologics, LLC · PMA 2011
- Pepgen 15Ceramed Corp. · PMA 2008
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.